Maximal tumor eradication for patients with oligometastatic prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of a combination treatment involving neoadjuvant apalutamide, androgen deprivation therapy (ADT), radical prostatectomy, extended lymph node dissection, and radiotherapy for patients diagnosed with oligometastatic prostate cancer. The study is designed to refine management strategies for metastatic hormone-sensitive prostate cancer (mHSPC) in China, where early detection is less common. By focusing on a comprehensive treatment approach, the trial seeks to improve survival rates and quality of life for affected patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age less than 75 years
* EORTC QLQC-30 score 2
* Life expectancy of 10 years
* Patients with oligometastatic prostate cancer on clinicopathological assessment
* Patients are suitable for radiotherapy and prostatectomy surgery
* Patients agree to participate in the study and sign the informed consent form before enrollment

Exclusion Criteria:

* Tumor related fracture
* Cannot accept radiotherapy
* Visceral metastasis
* Serious infection
* Thromboembolism history
* Not effectively controlled cardiovascular complications

Where it's running

• RenJi hospital, school of Medicine, Shanghai Jiao Tong University
  Shanghai, China Recruiting

Study contacts

• Study coordinator: JiaHua Pan, Doctor
• Email: jiahua.pan@outlook.com
• Phone: +8613916989510

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer

  This registry follows men with new, limited metastatic prostate cancer who receive targeted radiotherapy to the prostate and all visible metastases to see how they do over time in real-world care.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07686016

• Comprehensive radiotherapy to all metastases plus primary prostate radiotherapy versus prostate-only radiotherapy for men with oligometastatic prostate cancer

  This tests whether adding radiation to all PSMA-PET-visible metastases along with standard systemic therapy helps men with newly diagnosed oligometastatic prostate cancer stay progression-free longer than treating the prostate alone.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality and 2 other locations · NCT07015138

• Genomic biomarker-guided therapy for advanced prostate cancer

  This study is testing if personalized treatment based on genetic markers can help men with advanced prostate cancer before surgery.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06387056

• Combining immune therapy and radiation for prostate cancer treatment

  This study is testing a new treatment that combines immune therapy drugs with targeted radiation to see if it helps men with a specific type of prostate cancer live longer and feel better.

  Recruiting Phase 2 Columbia University · New York, New York · NCT05915442

• Using Lu-PSMA with SABR for treating oligometastatic prostate cancer

  This study is testing whether adding a special targeted therapy called Lu-PSMA to radiation treatment can help people with a few spots of prostate cancer live longer without their cancer getting worse.

  Recruiting at 4 sites Phase 2 Peter MacCallum Cancer Centre, Australia · St Leonards, New South Wales and 3 other locations · NCT05560659

• Comparing different radiation therapies for treating oligometastatic prostate cancer

  This study is testing whether new types of radiation therapy can help men with oligometastatic prostate cancer feel better and live longer compared to standard treatment.

  Recruiting at 3 sites British Columbia Cancer Agency · Kelowna, British Columbia and 3 other locations · NCT04610372

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.